Will EU prescribers be swayed by AstraZeneca’s Etcamah case?

AstraZeneca’s case is likely to resonate with EU prescribers because Etcamah (camizestrant) targets a clear treatment gap:
patients with ER-positive, HER2-negative advanced or metastatic breast cancer whose tumors develop an ESR1 mutation while they are still benefiting from first-line endocrine therapy plus a CDK4/6 inhibitor.

The pivotal SERENA-6 evidence showed longer progression-free survival when patients switched to camizestrant after ESR1 mutation detection, rather than continuing the same aromatase-inhibitor/CDK4/6-inhibitor regimen. The EMA described the benefit as improved progression-free survival, while overall-survival data remain immature.

The EU authorization is unusually flexible:
Etcamah can be combined with palbociclib, ribociclib, or abemaciclib. AstraZeneca positions it as the first next-generation oral SERD and complete estrogen-receptor antagonist approved in this first-line molecularly selected setting.

Adoption will not be automatic. Prescribers and health systems will scrutinize the size and durability of the benefit, the absence so far of demonstrated overall-survival improvement, tolerability, comparative value versus later-line oral SERDs and other targeted options, and local reimbursement decisions.

Routine implementation also requires serial ESR1 testing—plasma or tumor testing every three months until a mutation is detected—plus access to an appropriate CE-marked or validated assay. Testing capacity, turnaround time, and coordination between oncologists and laboratories could limit uptake.

Bottom line:
EU prescribers are likely to be cautiously favorable, especially in centers already using ctDNA-guided treatment and familiar with CDK4/6 inhibitors. Broad prescribing will depend less on AstraZeneca’s positioning than on national reimbursement, testing infrastructure, real-world experience, and whether future data confirm a survival or quality-of-life advantage.